A multicenter randomized trial shows PLD+carboplatin delivers non‑inferior PFS and significantly lower neurotoxicity and alopecia vs paclitaxel+carboplatin in 1L epithelial ovarian cancer. A promising taxane‑sparing option.
🔗 buff.ly/umFC4iX
#OvarianCancer #GynOnc #Chemotherapy #PLD #Paclitaxel
🎉 Congrats to Sam Lopez Alvarez for being selected to have a poster at the Dept of Bioinformatics Conference this March! 🙌 And a huge shoutout to Stephanie Tanis for securing a short talk at the event! 👏 Check out more: medschool.cuanschutz.edu/dbmi/event
#Bioinformatics #CUAnschutz #GynOnc
New gynecologic oncology research from Dr. Gary Altwerger and colleagues: chemo outcomes, minimally invasive surgical techniques, and innovative approaches to complex clinical challenges in HIPEC.
Links in the thread below.
#UChicagoMedicine #UChicago #GynOnc
New in Gynecologic Oncology: Dr. Han Cun’s review “Radiation Therapy for the Gynecologic Oncologist” highlights advances in IMRT, SBRT, proton therapy and brachytherapy.
Read: loom.ly/oajs9U0
#GynecologicOncology #GynOnc #UChicagoMedicine
COMING TODAY #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
REGISTER HERE TO WATCH: buff.ly/xwD5G2D
6PM CET and 12 Noon EST, Free and always relevant, however REGISTRATION is Necessary
Come Join our ESGO GynOnc Faculty for a Year in REVIEW in #GynOnc
📣ESMO #ClinicalPracticeGuideline Express Update on #EpithelialOvarianCancer:
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
The 2024 Ovarian Cancer Think Tank brought experts together to tackle questions in #GynOnc research. Explore key insights in the white paper - Ovarian Cancer Think Tank: The Use of Integrated AI and Computational Biology in Ovarian Cancer Diagnosis and Treatment #CUAnschutz
bit.ly/4pBuYx7
Coming February 5th: #GynOnc ESGO DAY🚨 The 6th Annual OncoAlert Colloquium
REGISTER👉 buff.ly/UDfpkP8
European Society of Gynaecological Oncology - ESGO
Welcome Lily Elizabeth Feldman, PhD! 🎉
Lily joins Dr. Bitler’s Gyn Oncology Research Group (GORG) at CU Anschutz as a new postdoctoral fellow. She completed her PhD in Pharmacology & Molecular Medicine and is also the Faculty Innovations Program Director at CU Innovations. 🧬
#CUAnschutz #GynOnc
Congrats to Scott Lin, MD, PhD Candidate, on being accepted into the PhRMA Foundation’s Predoctoral Drug Discovery Fellowship🎉50 researchers are selected for a share of $3.7M in funding to shape the future of drug discovery & translational medicine🌟 #GynOnc #CUAnschutz
View Article: bit.ly/4aaHUX0
Drs. Brad Corr and Ben Bitler launched a Phase 1 clinical trial for a promising combination therapy to tackle resistant ovarian cancer. This groundbreaking research could offer new hope to patients #OvarianCancer #GynOnc #CUAnschutz 🧬🎉
Read the Press Release: bit.ly/3MjeXxY
@uccc-gorg.bsky.social
Levi Watson, PhD, will be presenting on “Hematopoietic Stem Cell–Derived Adipocytes Influence the Ovarian Cancer Microenvironment” at the Ovarian Cancer Midwest Focus (OCMF) Conference in Minneapolis, MN, on November 10–11, 2025. For more information, visit: bit.ly/3JJy1oa
#CUAnschutz #GynOnc
Victoria’s Secret Global Fund for Women’s Cancers Career Development Award 2025: Advancing Research in Breast and Gynecologic Cancers
oncodaily.com/insight/vict...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GynOnc
✨Dr. Brad Corr, A CU Gynecologic Oncologist, is dispelling clinical trial myths! 🧪✅ Safe, innovative treatments empower patients to make informed care decisions.
📖 Read more: bit.ly/4hAKCGW
#OvarianCancer #GynOnc #CUAnschutz
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
Oncology experts will be joining our friends and collaborators at COR2ED in Berlin for #ESMO25
Coming Soon👉 cor2ed.com/esmo-2025/up...
They will share their insights on the latest data on #BladderCancer #KidneyCancer #ProstateCancer #LungCancer #BreastCancer #GynOnc and Upper GI Cancers
Sign up
Join us for the Pharmacology Seminar Series as Dr. Elizabeth Woodruff discusses how chronic stress influences #HGSC progression and immune response through adrenergic signaling in the omentum. #OvarianCancer #GynOnc #CUAnschutz
Date 📅: Mon, 10/20/25, 12:00 PM MST
Location📍: RC1 North, Room 6107
⭐ Felix Hilpert, MD, stresses that age/frailty shouldn’t preclude ovarian cancer therapy: chemo & surgery can extend survival in older pts:
🎥 buff.ly/MUxPkAI
#ESMOGynae25 #GynOnc #GyncSM
Toni Moses, RN, is battling stage IV ovarian cancer while helping others—and participating in a trial led by Dr. Brad Corr & the CU Ovarian Cancer Innovations Group. 💙 Read her powerful story: news.cuanschutz.edu/cancer-cente...
#OvarianCancer #GynOnc #CUAnschutz
🎥 Domenica Lorusso, MD, PhD, reports relacorilant + nab-paclitaxel improved PFS & OS in platinum-resistant ovarian cancer w/ consistent safety:
➡️https://buff.ly/M7ojYej
#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate
🎥 Alberto Farolfi, MD, reports ctDNA did not align with tissue molecular analysis in the RAMP 201 trial for cervical cancer. Highlights limitations of ctDNA as a reliable biomarker in this setting:
➡️ buff.ly/pQUGuhR
#ESMOGynae25 #GynOnc #Gyncsm
Division Director #MichaelMcHaleMD & #GynOnc team supporting #WearTeal Steps Walk for #OvarianCancer. We are grateful Ovarian Cancer Alliance of San Diego has graciously supported @ucsd-obgyn.bsky.social GynOnc research to make a significant impact on improving #cancer care for our community.
🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer:
➡️https://buff.ly/ysRSWzX⬅️
@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM
MASCC - New Study Explores Sexual Health After Chemotherapy for Breast and Gynecologic Cancer
@cancercaremascc.bsky.social
oncodaily.com/science/gyne...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MASCC #GynOnc #SexualHealth #BreastCancer #GynecologicCancer
🎥 Angeles Secord, MD, from @dukehealth.bsky.social addresses sequencing challenges of ADCs in ovarian cancer. With FDA approvals for mirvetuximab soravtansine and T-DXd, trials are essential for guiding target and payload choices.
🔗https://buff.ly/q23sXHU
#ESMOGynae25 #Gyncsm #GynOnc #ImmunoOnc
Help us welcome Drs. Katharine Linder and Daisy Cruz, our new CU GynOnc fellows joining the University of Colorado GynOnc Research Group (GORG) Lab this Fall 2025! Excited for the expertise and passion they'll bring to advancing women’s cancer research 🎉🎉 #GynOnc #CUAnschutz #OvarianCancer
🎉 Thank you to all who joined the quarterly Virtual GynOnc Research Series!
Special thanks to Scott Lin, MD, PhD Candidate, for sharing his expertise on PARP inhibitor research—from its origins to the approval process.
🎥 Watch: https://loom.ly/sjq1g-0
#GynOnc #CUAnschutz #OvarianCancer
Synapse: Your Connection to our MSK Authors
Meet: Matthew Laurence Flint
Research Focus: Graduate Staff; Fellow
#OvarianCancerResearch #FOLR1TargetedTherapy
#Mirvetuximab #ADCTherapy #OncologyOutcomes #TargetedCancerTherapy #GynOnc #CancerResearch
synapse.mskcc.org/synapse/work...
Congrats to Drs. Ben Bitler and Jim Lambert on receiving an award from Golfers Against Cancer to advance ovarian cancer immunogenic cell death (ICD) research — pushing boundaries in cancer research #OvarianCancer #GynOnc #CUAnschutz 👏👏 @uccc-gorg.bsky.social
Congratulations to Dr. Ogamba and this phenomenal group of investigators on execution of this large patient-reported outcomes study! And many thanks for the opportunity to contribute our PRO & financial toxicity methodologic expertise. #gyncsm #gynonc #medsky #oncsky
www.nature.com/articles/s41...
